Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

This randomized trial of the BNT162b2 vaccine involved 2260 adolescents 12 to 15 years of age. Similar levels of antibody to SARS-CoV-2 were elicited in the 12-to-15-year-old participants and in 16-to-25-year-old participants in a parallel trial. Among participants with no evidence of previous infec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 2021-07, Vol.385 (3), p.239-250
Hauptverfasser: Frenck, Robert W, Klein, Nicola P, Kitchin, Nicholas, Gurtman, Alejandra, Absalon, Judith, Lockhart, Stephen, Perez, John L, Walter, Emmanuel B, Senders, Shelly, Bailey, Ruth, Swanson, Kena A, Ma, Hua, Xu, Xia, Koury, Kenneth, Kalina, Warren V, Cooper, David, Jennings, Timothy, Brandon, Donald M, Thomas, Stephen J, Türeci, Özlem, Tresnan, Dina B, Mather, Susan, Dormitzer, Philip R, Şahin, Uğur, Jansen, Kathrin U, Gruber, William C
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent Medicine
Adolescents
Adverse events
Age
Confidence intervals
Coronavirus
Coronaviruses
COVID-19
COVID-19 vaccines
Diaries
Disease transmission
Hepatitis
Herd immunity
Illnesses
Immune response
Immunization
Immunogenicity
Infections
Infectious Disease
Original
Pandemics
Pediatrics
Placebos
Population
Safety
Severe acute respiratory syndrome coronavirus 2
Statistical analysis
Teenagers
Testing laboratories
Vaccine efficacy
Vaccines
Young adults
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This randomized trial of the BNT162b2 vaccine involved 2260 adolescents 12 to 15 years of age. Similar levels of antibody to SARS-CoV-2 were elicited in the 12-to-15-year-old participants and in 16-to-25-year-old participants in a parallel trial. Among participants with no evidence of previous infection, no cases of Covid-19 were diagnosed in vaccine recipients, as compared with 16 cases in placebo recipients.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2107456